Treatment-resistant prurigo nodularis

Sree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wa...

Full description

Bibliographic Details
Main Authors: Kolli SS, Haidari W, Feldman SR
Format: Article
Language:English
Published: Dove Medical Press 2019-05-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
Online Access:https://www.dovepress.com/treatment-resistant-prurigo-nodularis-peer-reviewed-article-CCID
id doaj-de69c5f5cfcc49c5bb9dc828143e6287
record_format Article
spelling doaj-de69c5f5cfcc49c5bb9dc828143e62872020-11-24T20:43:28ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152019-05-01Volume 1234534645735Treatment-resistant prurigo nodularisKolli SSHaidari WFeldman SRSree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Kowalski et al describe various treatment approaches to achieve better outcomes in treatment-resistant prurigo nodularis in an article entitled, “Treatment-resistant prurigo nodularis: challenges and solutions.”1 Many excellent approaches are suggested, but the issue of nonadherence to topical therapies may be an overlooked issue commonly contributing to “treatment-resistance.” Often, in the face of “resistant” disease, patients may be prescribed more complicated or risky treatment regimens that make adherence even more difficult. Such strategies may not be the most effective ones when poor adherence underlies seemingly treatment-resistant prurigo nodularis.Treatment-resistance can often be overcome by measures that improve adherence. Even patients with severe, refractory atopic dermatitis respond rapidly to midpotency topical corticosteroids applied in the inpatient setting. Prurigo nodularis is often secondary to atopic dermatitis and psoriasis. In patients with atopic dermatitis or psoriasis that was “resistant” to topical corticosteroids, all patients treated with an easy to use topical corticosteroid spray improved rapidly when coupled with adherence promoting measures (telephone reminders, patient education and frequent office visits). Adherence to topical treatments is bad in the short-term and abysmal in the long-term.2–4 Perhaps one of the best approaches when faced with treatment-resistant disease is to simplify the treatment regimen and encourage good use of treatment, or better yet, bring patients in to assure the treatment is administered. View the original paper by Kowalski and colleagues https://www.dovepress.com/treatment-resistant-prurigo-nodularis-peer-reviewed-article-CCIDTreatment-resistant diseaseprurigo nodularisatopic dermatitispsoriasisadherencestrategies
collection DOAJ
language English
format Article
sources DOAJ
author Kolli SS
Haidari W
Feldman SR
spellingShingle Kolli SS
Haidari W
Feldman SR
Treatment-resistant prurigo nodularis
Clinical, Cosmetic and Investigational Dermatology
Treatment-resistant disease
prurigo nodularis
atopic dermatitis
psoriasis
adherence
strategies
author_facet Kolli SS
Haidari W
Feldman SR
author_sort Kolli SS
title Treatment-resistant prurigo nodularis
title_short Treatment-resistant prurigo nodularis
title_full Treatment-resistant prurigo nodularis
title_fullStr Treatment-resistant prurigo nodularis
title_full_unstemmed Treatment-resistant prurigo nodularis
title_sort treatment-resistant prurigo nodularis
publisher Dove Medical Press
series Clinical, Cosmetic and Investigational Dermatology
issn 1178-7015
publishDate 2019-05-01
description Sree S Kolli,1 Wasim Haidari,1 Steven R Feldman1–31Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Kowalski et al describe various treatment approaches to achieve better outcomes in treatment-resistant prurigo nodularis in an article entitled, “Treatment-resistant prurigo nodularis: challenges and solutions.”1 Many excellent approaches are suggested, but the issue of nonadherence to topical therapies may be an overlooked issue commonly contributing to “treatment-resistance.” Often, in the face of “resistant” disease, patients may be prescribed more complicated or risky treatment regimens that make adherence even more difficult. Such strategies may not be the most effective ones when poor adherence underlies seemingly treatment-resistant prurigo nodularis.Treatment-resistance can often be overcome by measures that improve adherence. Even patients with severe, refractory atopic dermatitis respond rapidly to midpotency topical corticosteroids applied in the inpatient setting. Prurigo nodularis is often secondary to atopic dermatitis and psoriasis. In patients with atopic dermatitis or psoriasis that was “resistant” to topical corticosteroids, all patients treated with an easy to use topical corticosteroid spray improved rapidly when coupled with adherence promoting measures (telephone reminders, patient education and frequent office visits). Adherence to topical treatments is bad in the short-term and abysmal in the long-term.2–4 Perhaps one of the best approaches when faced with treatment-resistant disease is to simplify the treatment regimen and encourage good use of treatment, or better yet, bring patients in to assure the treatment is administered. View the original paper by Kowalski and colleagues 
topic Treatment-resistant disease
prurigo nodularis
atopic dermatitis
psoriasis
adherence
strategies
url https://www.dovepress.com/treatment-resistant-prurigo-nodularis-peer-reviewed-article-CCID
work_keys_str_mv AT kolliss treatmentresistantprurigonodularis
AT haidariw treatmentresistantprurigonodularis
AT feldmansr treatmentresistantprurigonodularis
_version_ 1716819818858938368